Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas
- PMID: 17604583
- DOI: 10.1016/j.anl.2007.02.004
Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas
Abstract
Objectives: Concurrent chemoradiotherapy (CCR) was given for the previously untreated T4 hypopharyngeal and laryngeal squamous cell carcinoma patients and the response and survival rates were evaluated.
Patients and methods: A total of 23 patients, namely, 15 for hypopharynx and 8 for larynx were eligible. These patients were given cisplatin and 5-fluorouracil based chemotherapeutic regimens with conventional radiotherapy for a total dose of 66.6-70.2 Gy.
Results: Ten out of the 15 hypopharyngeal carcinoma patients and 4 out of the 8 laryngeal carcinoma patients showed a complete response at the primary sites. The 5-year disease-specific survival rate was 59.4% in all the patients, 51.9% in the hypopharyngeal carcinoma patients, and 71.0% in the laryngeal patients. Seven out of the 12 resectable hypopharyngeal carcinoma patients and 4 out of 8 laryngeal carcinoma patients were able to do without total laryngectomy.
Conclusions: Based on these results, the survival rate in the hypopharyngeal and laryngeal T4 carcinoma patients treated by CCR seems to be satisfactory and the possibility of organ preservation for the advanced patients is indicated.
Similar articles
-
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.Acta Otolaryngol. 2010;130(1):150-5. doi: 10.3109/00016480902914080. Acta Otolaryngol. 2010. PMID: 19449227 Clinical Trial.
-
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68. doi: 10.1016/j.ijrobp.2007.03.013. Epub 2007 May 9. Int J Radiat Oncol Biol Phys. 2007. PMID: 17493769
-
Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.Acta Otolaryngol. 2006 Apr;126(4):408-13. doi: 10.1080/00016480500401019. Acta Otolaryngol. 2006. PMID: 16608794
-
[Current role for induction chemotherapy in head and neck tumors].Laryngorhinootologie. 2008 Apr;87(4):237-43; discussion 244. doi: 10.1055/s-2007-995588. Laryngorhinootologie. 2008. PMID: 18365986 Review. German.
-
Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer.Onkologie. 2004 Aug;27(4):368-75. doi: 10.1159/000079090. Onkologie. 2004. PMID: 15347892 Review.
Cited by
-
Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro.J Oncol. 2012;2012:649605. doi: 10.1155/2012/649605. Epub 2012 Mar 26. J Oncol. 2012. PMID: 22545049 Free PMC article.
-
Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.BMC Cancer. 2010 Mar 18;10:102. doi: 10.1186/1471-2407-10-102. BMC Cancer. 2010. PMID: 20298550 Free PMC article.
-
Organ preservation strategies: Review of literature and their applicability in developing nations.South Asian J Cancer. 2014 Jul;3(3):147-50. doi: 10.4103/2278-330X.136764. South Asian J Cancer. 2014. PMID: 25136519 Free PMC article. Review.
-
Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.Strahlenther Onkol. 2013 Jan;189(1):26-32. doi: 10.1007/s00066-012-0178-0. Epub 2012 Nov 18. Strahlenther Onkol. 2013. PMID: 23161117
MeSH terms
Substances
LinkOut - more resources
Full Text Sources